Halvard & Pike Apothecary of Portland, Maine closes after 4 years
A proper account of an operation that existed, and of what closing it cost.
The archive — 2024
Page 19 of 68 of this archive, newest first.
What a 33% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
VendorInvestigate result on a Guangzhou liraglutide lot lands 3.6 points above the supplier’s stated figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Why people actually stop, in the order they actually stop
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
What “LC-MS: conforms” tells a reader, which is almost nothing
What the Journal asks for when it writes to a supplier about an identity claim, and how often it gets it.
A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Nigeria health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
How far back does this document actually reach?
The interval between manufacture and analysis is the most under-read figure on the page, and the one most likely to matter by the time a vial is opened.
Why a 0.036-dalton difference is the hardest number in peptide identity
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
The advice is mostly reasonable. The certainty is not earned.
A tour of the source literatures, with an assessment of how far each legitimately reaches.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The consolidator trading as Meridian Freight Partners closes after 15 years
A proper account of an operation that existed, and of what closing it cost.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 16% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
Stepping down against stopping: two decisions treated as one
These agents produce no dependence and no withdrawal syndrome. What a taper would be for is therefore a real question rather than an obvious one.
STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a Homopeptide orforglipron lot at 99.1%, against 98.4% on the certificate
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 9-day notice: how a compounding wind-down works in Singapore
The document is four pages. Three of them are about dates.
What STEP 4 and SURMOUNT-4 actually established
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
Do you need the top of the ladder?
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
The batch number is the only thing connecting the page to the vial
The interval between manufacture and analysis is the most under-read figure on the page, and the one most likely to matter by the time a vial is opened.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 18 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What the trials monitored, and what that implies about routine practice
Timing is the whole of the post-cessation panel: draw it too early and it measures the treatment period.
Where the receptor is: a tissue-by-tissue account of tirzepatide’s reach
The same receptor population that produces the therapeutic effect produces the commonest adverse one.
STEP 8 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.